1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Israel >
  5. Leap Therapeutics Acquires MacroCure

M&A Deal Summary

Leap Therapeutics Acquires MacroCure

On August 29, 2016, Leap Therapeutics acquired life science company MacroCure

Acquisition Highlights
  • This is Leap Therapeutics’ 1st transaction in the Life Science sector.
  • This is Leap Therapeutics’ 1st transaction in Israel.

M&A Deal Summary
Date 2016-08-29
Target MacroCure
Sector Life Science
Buyer(s) Leap Therapeutics
Deal Type Add-on Acquisition
Advisor(s) Raymond James - Investment Banking (Financial)

Target

MacroCure

Kiryat Matalon, Petach Tikva, Israel
MacroCure Ltd. is a biotechnology company focused on the development and commercialization of advanced cell therapy products. MacroCure currently manufactures and markets its lead product, CureXcell™, in Israel for difficult-to-heal wound treatment. MacroCure plans to begin a multinational Phase III study under an SPA, in the US, Canada and Israel in the second quarter 2011, for lower extremity ulcers in diabetic patients.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Leap Therapeutics

Cambridge, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Leap Therapeutics, Inc. is an immuno-oncology company with two clinical stage programs. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Israel M&A 1 of 1
Year: 2016 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal